Track topics on Twitter Track topics that are important to you
VetStem Biopharma has spun out Personalized Stem Cells, Inc. and licensed it with human autologous stem cell authority to begin human clinical trials using adipose stem cell technology pioneered and patented by VetStem.
POWAY, Calif. (PRWEB) February 19, 2019
VetStem Biopharma has long been a leader in veterinary stem cell therapy with clinical, regulatory and manufacturing experience. In October 2018, VetStem authorized the formation of Personalized Stem Cells, Inc (“PSC”), a human adipose stem cell company. VetStem has licensed to PSC its stem cell patents, data, and FDA filings to launch into human stem cell clinical therapy. PSC will conduct a series of FDA-IND approved clinical trials starting with uses in orthopedics. With one of the first cGMP cell manufacturing facilities in California, VetStem will be the contract manufacturer of stem cells for use in these Phase I human studies by the PSC network of human physician investigators.
The current environment of in-office manufacturing of stem cells by physicians has come under serious regulatory action by the FDA, FTC, and the Federation of State Medical Boards. It is clear that the only allowed use of stem cells will be through legitimate FDA clinical trials and with manufacturing in a controlled environment. VetStem has recruited experienced executive management including CEO Mike Dale, a co-founder of VetStem and experienced serial entrepreneur.
“This is a unique opportunity in history to have a profound influence on the development and adoption of a game-changing medical technology” says Mr. Dale. “Regenerative medicine has opened up new possible treatment options for a wide array of conditions that are not effectively treated with today’s medicines.” VetStem CEO and co-founder, Dr. Bob Harman, stated, ”We believe that we can really jumpstart human stem cell therapy using the VetStem data and experience and Mr. Dale will lead PSC rapidly forward with legitimate clinical trials.”
PSC has successfully completed its seed investment round and has begun operations. The first clinical trials are anticipated to begin in early 2019. For more information about becoming an investigator or enrolling in a clinical trial, email Mike Dale at email@example.com or visit the PSC website at http://www.pscells.com.
VetStem is a 75% owner of PSC and provides contract services including cGMP manufacturing for PSC. VetStem is in the process of raising a final round of capital to complete its approved pivotal FDA licensing trial for canine osteoarthritis.
About VetStem Biopharma, Inc.
VetStem Biopharma is a veterinarian-lead Company that was formed in 2002 to bring regenerative medicine to the profession. This privately held biopharmaceutical enterprise, based near San Diego, California, currently offers veterinarians an autologous stem cell processing service (from patients’ own fat tissue) among other regenerative modalities. With a unique expertise acquired over the past 15 years and 17,000 treatments by veterinarians for joint, tendon or ligament issues, VetStem has made regenerative medicine applications a therapeutic reality. The VetStem team is focused on developing new clinically practical and affordable veterinary solutions that leverage the natural restorative abilities present in all living creatures. In addition to its own portfolio of patents, VetStem holds exclusive global veterinary licenses to a large portfolio of issued patents in the field of regenerative medicine.
For the original version on PRWeb visit: https://www.prweb.com/releases/vetstem_biopharma_launches_human_stem_cell_company_in_san_diego/prweb16099119.htmNEXT ARTICLE
Track and monitor developments in stem cell research and commercial development. Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry. BioPort...
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...